Investigational Therapies and Epilepsy Care

While there is currently no cure for SLC35A2-CDG, modern medicine is investigating “targeted” therapies that aim to address the specific biological problem in your child’s cells. One potential investigational therapy is the use of a simple sugar called D-galactose ^[1].

D-Galactose: Investigating the Transport Defect

As you may recall from the diagnosis page, the primary problem in SLC35A2-CDG is that a “truck” (the SLC35A2 transporter) is not moving enough UDP-galactose into the cell’s “packaging center” (the Golgi).

D-galactose supplementation is being studied as a “substrate therapy.” By giving your child extra galactose orally, which is converted to UDP-galactose inside the cells, doctors hope to increase the available UDP-galactose substrate inside the cell. This may exploit any residual transport activity and help it find its way into the Golgi ^[1].

The Evidence and Safety

In clinical studies, researchers have investigated protocols to introduce this sugar safely, though it is important to know the evidence is limited to a very small, uncontrolled study:

• Clinical Gains: In a study of 10 children, 5 showed noticeable developmental progress, such as improved head control, better responses to sights and sounds, and improved ability to chew or swallow ^[1]. However, developmental changes may reflect concurrent therapies or natural variation, and one child had no clinical improvement.
• Measurement: Doctors track these changes using the Nijmegen Pediatric CDG Rating Scale (NPCRS). This scale measures physical health and developmental progress; in studies, some children’s total scores improved significantly after starting therapy ^[1].
• Prescription Only: D-galactose must only be used as a specialist-directed or pharmacy-supplied product, and the treating team must define laboratory and clinical monitoring based on individual needs.

Potential Side Effects

The most common known side effect is gastrointestinal discomfort, such as abdominal pain or diarrhea ^[2]. This usually happens if the dose is increased too quickly or given all at once. Spacing the doses out more or slightly reducing the dose often resolves these issues ^[2]. Long-term safety data remains uncertain, and families must review galactose metabolism contraindications with their metabolic specialist.

Managing Seizures and Infantile Spasms

Seizures are often the most challenging part of SLC35A2-CDG. Because the underlying cause is a metabolic “supply chain” problem, standard seizure medications may not always work perfectly. This is known as drug-resistant epilepsy ^[3].

• Infantile Spasms: If your child has this specific type of seizure, urgent medical evaluation is required. First-line selection varies but often involves high-dose ACTH (a hormone injection) or vigabatrin ^[4].
• Risks to Monitor: These powerful therapies have important safety monitoring requirements. ACTH and steroid treatments can cause systemic effects like hypertension, infection risk, and glucose changes ^[5]. Vigabatrin has potentially permanent visual-field toxicity ^[4]. Never stop or change antiseizure medicines without the epilepsy team.
• Ketogenic Diet: Some families have tried the ketogenic diet. While it can be helpful for some types of epilepsy, it has shown mixed results in SLC35A2-CDG, with some children finding it only partially effective ^[6][3].
• The “Galactose Effect”: Interestingly, some parents and doctors have reported that seizures become easier to manage or decrease in frequency after the child has been on D-galactose therapy for some time, but seizure benefit remains uncertain ^[1][2].

Comprehensive Supportive Care

Because this condition affects many parts of development, a “team” approach is the standard of care:

• Physical and Occupational Therapy (PT/OT): Focused on improving muscle tone (hypotonia) and helping your child reach motor milestones like sitting or grasping ^[7].
• Speech and Swallow Therapy: Essential for children who have difficulty feeding or who are non-verbal ^[1].

Treatment is a marathon, not a sprint. While investigational therapies like D-galactose are not a “quick fix,” coordinated care represents a significant step forward in helping children with SLC35A2-CDG manage their symptoms safely.